Akorn Recalls Sulfamethoxazole and Trimethoprim Oral Suspension for Dissolution Failure
Akorn, Inc. is recalling specific lots of Sulfamethoxazole and Trimethoprim Oral Suspension because the sulfamethoxazole component failed to meet dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which indicates a situation where use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences. The hazard is a failure to meet dissolution specifications, which is a quality issue rather than a direct safety hazard like contamination or mislabeling of a common allergen.
Plain-English summary
Akorn, Inc. is recalling 326,666 bottles of Sulfamethoxazole and Trimethoprim Oral Suspension, USP, 200 mg/40 mg per 5 mL, Grape Flavor, 16 fl oz (473 mL). The product is manufactured by Hi-Tech Pharmacal Co. Inc. and distributed nationwide and in Puerto Rico.
The recall was initiated because the product failed to meet dissolution specifications for the sulfamethoxazole component. This means the drug may not dissolve in the body as intended, potentially affecting its therapeutic effectiveness.
Consumers should check their medication bottles for the specific lot numbers and expiration dates listed in the recall notice. If the product matches the recalled lots, consumers should stop using it and contact their pharmacist or healthcare provider for a replacement or further instructions.
The recalled product
- Product
- SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION, USP,200 mg/ 40 mg per 5mL, GRAPE FLAVOR, 16 fl oz (473 mL) bottles (NDC 50383-0824-16), Rx only, HI-TECH PHARMACAL CO. INC, Amityville, NY 11701
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Antibiotic
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # 618358
- Exp. 11/15/2015
- Lot # 618646
- Exp. 11/18/2015
- Lot # 618649
- Exp. 11/19/2015
- Lot # 618652
- Exp. 11/20/2015
- Lot # 618746
- Exp. 11/26/2015
- Lot # 618749
- Exp. 11/27/2015
- Lot # 618934
- Exp. 12/5/2015
- Lot # 618940
- Exp. 12/6/2015
- Lot # 618946
- Exp. 12/8/2015
- Lot # 621496
- Exp. 5/13/2016
Distribution
Part of a larger recall action
This product is one of 3 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17